Elixinol Wellness (ASX:EXL) First Half 2023 Results
Key Financial Results
Revenue: AU$3.46m (up 7.4% from 1H 2022).
Net loss: AU$3.40m (loss narrowed by 52% from 1H 2022).
AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Elixinol Wellness Earnings Insights
Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Personal Products industry in Oceania.
The company's shares are down 18% from a week ago.
We don't want to rain on the parade too much, but we did also find 6 warning signs for Elixinol Wellness (4 shouldn't be ignored!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.